Nuo Therapeutics (Nuo Therapeutics) Total Inventories : $0.21 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Total Inventories?

Nuo Therapeutics's total inventories for the quarter that ended in Mar. 2024 was $0.21 Mil. Nuo Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.21 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Nuo Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Nuo Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 376.63.

Inventory Turnover measures how fast the company turns over its inventory within a year. Nuo Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.24.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Nuo Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.90.

Nuo Therapeutics Total Inventories Historical Data

The historical data trend for Nuo Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics Total Inventories Chart

Nuo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

0.24

0.21

Nuo Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															0.21	0.23	0.21	0.21	0.21

Nuo Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Nuo Therapeutics (OTCPK:AURX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Nuo Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.366	+	0.75 * 0.23	+	0.5 * 0.211	-	0.909
-	0	-	0)	/	44.2415
=	-0.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Nuo Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0.2105	/	0.051	*	365 / 4
	=	376.63

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Nuo Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0.051	/	0.2105
	=	0.24

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Nuo Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0.2105	/	0.235
	=	0.90

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Nuo Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuo Therapeutics (Nuo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

8285 El Rio, Suite 190, Houston, TX, USA, 77054

Website

https://www.nuot.com

Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.

Executives

Charles E Sheedy	10 percent owner	TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden	director, officer: CEO, CFO	2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky	director	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer	director
Paul Mintz	director	C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen	officer: CSO	11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman	director	3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer	officer: CHIEF COMMERCIAL OFFICER	C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross	officer: SEE REMARKS	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc	10 percent owner, other: May be part of a 13(d) group	C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr	10 percent owner, other: May be part of a 13(d) group	315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke	10 percent owner, other: May be part of a 13(d) group	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del	director	C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark	10 percent owner, other: May be part of a 13(d) group	C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713